A critical review of HER2-positive gastric cancer evaluation and treatment: From trastuzumab, and beyond

被引：85

作者：

Gomez-Martin, Carlos ^{[1
,2
,3
]}

Lopez-Rios, Fernando ^{[3
]}

Aparicio, Jorge ^{[4
]}

Barriuso, Jorge ^{[5
]}

Garcia-Carbonero, Rocio ^{[6
]}

Pazo, Roberto ^{[7
]}

Rivera, Fernando ^{[8
]}

Salgado, Mercedes ^{[9
]}

Salud, Antonieta ^{[10
]}

Vazquez-Sequeiros, Enrique ^{[11
]}

Lordick, Florian ^{[12
]}

机构：

[1] 12 Octubre Univ Hosp, Gastrointestinal Canc Unit, Madrid 28041, Spain

[2] 12 Octubre Univ Hosp, Early Drug Dev Unit, Div Med Oncol, Madrid 28041, Spain

[3] Univ San Pablo CEU, Fac Med, Hosp Univ Madrid Sanchinarro, Lab Dianas Terapeut,Ctr Integral Oncol Clara Camp, Madrid, Spain

[4] Hosp Univ & Politecn La Fe, Dept Med Oncol, Valencia, Spain

[5] La Paz Univ Hosp IdIPAZ, Dept Oncol, Upper GI Unit, Madrid, Spain

[6] Univ Seville, CSIC, HUVR, Med Oncol Dept,Inst Biomed Sevilla IBIS, Seville, Spain

[7] Hosp Univ Miguel Servet, Dept Med Oncol, Zaragoza, Spain

[8] Univ Hosp Marques de Valdecilla, Dept Med Oncol, Santander, Spain

[9] Complejo Hosp Ourense, Dept Med Oncol, Orense, Spain

[10] Hosp Univ Arnau de Vilanova Lleida, Dept Med Oncol, Lleida, Spain

[11] Hosp Ramon & Cajal, Dept Gastroenterol, E-28034 Madrid, Spain

[12] Univ Canc Ctr Leipzig, Univ Clin Leipzig, Leipzig, Germany

来源：

CANCER LETTERS | 2014年 / 351卷 / 01期

关键词：

HER2; Gastric cancer; Trastuzumab; Review; IN-SITU HYBRIDIZATION; GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA; RANDOMIZED PHASE-III; BREAST-CANCER; HER2; STATUS; CLINICAL-PRACTICE; 1ST-LINE THERAPY; GASTROINTESTINAL-TRACT; GENE AMPLIFICATION; ANTITUMOR-ACTIVITY;

D O I：

10.1016/j.canlet.2014.05.019

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Identification of the importance of human epidermal growth factor receptor-2 (HER2) status, biomarker testing and the development of anti-HER2 treatments have changed the prognosis of breast and gastric cancers. The addition of trastuzumab to chemotherapy has improved outcomes for patients with HER2-positive metastatic adenocarcinoma of the stomach and gastroesophageal junction, but some relevant issues remain to be elucidated or will emerge with new drugs. This article reviews the current state of HER2 in gastric cancer focusing on diagnostic and anti-HER2 targeted treatment issues and the role of trastuzumab in localized disease, and its combination or integration with new therapies. (C) 2014 Elsevier Ireland Ltd. All rights reserved.

引用

页码：30 / 40

页数：11

共 120 条

[1]

Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial [J].

Ajani, Jaffer A. ;

Rodriguez, Wuilbert ;

Bodoky, Gyorgy ;

Moiseyenko, Vladimir ;

Lichinitser, Mikhail ;

Gorbunova, Vera ;

Vynnychenko, Ihor ;

Garin, August ;

Lang, Istvan ;

Falcon, Silvia .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (09) :1547-1553

[2]

[Anonymous], ASCO M S

[3]

[Anonymous], SURV RAT STOM CANC S

[4]

[Anonymous], J CLIN ONCOL S

[5]

[Anonymous], HERC SUMM PROD CHAR

[6]

[Anonymous], GASTRIC CANC

[7]

[Anonymous], P GI ASCO

[8]

[Anonymous], ASCO M S

[9]

[Anonymous], 2010, WHO CLASSIFICATION T

[10]

[Anonymous], FRONT ONCOL

← 1 2 3 4 5 6 7 8 9 10 →